TNF Pharmaceuticals Begins Trading Under New Nasdaq Stock Symbol TNFA Effective Before Market Open Today
| TNFA Stock | 1.27 0.02 1.55% |
About 62% of TNF Pharmaceuticals,'s investor base is looking to short. The analysis of overall sentiment of trading TNF Pharmaceuticals, stock suggests that many investors are alarmed at this time. The current market sentiment, together with TNF Pharmaceuticals,'s historical and current headlines, can help investors time the market. In addition, many technical investors use TNF Pharmaceuticals, stock news signals to limit their universe of possible portfolio assets.
TNF |
TNF Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company committed t
Read at businesswire.com
 |
TNF Pharmaceuticals, Fundamental Analysis
We analyze TNF Pharmaceuticals,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TNF Pharmaceuticals, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TNF Pharmaceuticals, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
TNF Pharmaceuticals, is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
TNF Pharmaceuticals, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TNF Pharmaceuticals, stock to make a market-neutral strategy. Peer analysis of TNF Pharmaceuticals, could also be used in its relative valuation, which is a method of valuing TNF Pharmaceuticals, by comparing valuation metrics with similar companies.
Peers
TNF Pharmaceuticals, Related Equities
| VALN | Valneva SE | 3.71 | ||||
| IPGP | IPG Photonics | 1.99 | ||||
| CTS | CTS | 0.98 | ||||
| NEOG | Neogen | 0.83 | ||||
| SNDA | Sonida Senior | 0.78 | ||||
| BNTX | BioNTech | 0.55 | ||||
| MMSI | Merit Medical | 0.48 | ||||
| CNTA | Centessa Pharmaceuticals | 3.59 |
Complementary Tools for TNF Stock analysis
When running TNF Pharmaceuticals,'s price analysis, check to measure TNF Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TNF Pharmaceuticals, is operating at the current time. Most of TNF Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of TNF Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TNF Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of TNF Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |